The founders of Topical Innovations are two medical doctors who work as pain physicians since more than a decade. They work together in a network of Dutch and international pain physicians.
JMKH is a professor in molecular pharmacology and a consultant for the pharmaceutical industry and for life science investors since more than 20 years.
DJK is a pain physician with expertise in the field of neuropathic pain and rehabilitation medicine since more than a decade.
Together they founded the Institute for Neuropathic Pain in 2008, a tertiary referral center for neuropathic pain patients. Patients and physicians from all over the world are consulting the Institute for Neuropathic Pain, to achieve the optimal treatment in case of complicated patients.
Topical Innovations currently explores partnering with a pharmaceutical developer to reach worldwide marketing of our topical formulations.
Drug Repositioning Expertise
Drug repositioning in the field of CNS disorders started to become a HOT issue since the beginning of this decade. Drugs previously developed in neurology, psychiatry and cardiovascular disorders are increasingly repositioned in neurology and pain medicine. Drug repositioning is an item of great interest, and phenytoin is quite suited for repositioning. The patent-protected-repositioning of phenytoin as a topical cream creates a number of development advantages such as significantly reduced time to market and development costs.
Research and Drug Development Expertise
Drug research and development in the field of CNS disorders and autacoid medicine is our passion.
Many years we worked in this field and coached and supported the research and development of many new leads.
In 2017, together with the psychopharmacologist professor Stephen Stahl from the University of San Diego, USA we published an authoritative review on the critical issues in developing topical analgesics:
Keppel Hesselink JM, Kopsky DJ, Stahl SM. Bottlenecks in the development of topical analgesics: molecule, formulation, dose finding, and phase III design. J Pain Res. 2017; 10: 635-641.
The reference list below lists some additional publications from the hands of the founders of Topical Innovations, in field of drug repositioning and drug R&D.
Keppel Hesselink JM, Kopsky DJ. Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. Journal of Neurology. 2017:1-5.
Keppel Hesselink JM. Phenytoin: a step by step insight into its multiple mechanisms of action—80 years of mechanistic studies in neuropharmacology. J Neurology March 27, 2017, DOI 10.1007/s00415-017-8465-4
Keppel Hesselink JM. Arguments to develop TRPV1 antagonist in neuropathic pain. Lessons for drug development. Clinical Research and Trials (CRT) 2017, DOI: 10.15761/CRT.1000165
Keppel Hesselink, JM. A Novel α2δ1 Agonist for Neuropathic Pain: NVA1309 of Novassay. J of Pharmacol & Clin Res. 2016; 1(5): 555575. DOI: 10.19080/JPCR.2016.01.555575
Keppel Hesselink JM. CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of ‘Spin’ In Scientic Writing? J of Pharmacol & Clin Res. 2017; 2(3): 555588. DOI: 10.19080/JPCR.2017.02.555588
Keppel Hesselink JM. NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned. Drug Dev Res. 2017 Feb 13. doi: 10.1002/ddr.21376.
Keppel Hesselink JM. Idalopirdine (LY483518, SGS518, Lu AE 58054) in Alzheimer disease: never change a winning team and do not build exclusively on surrogates. J of Pharmacol & Clin Res. 2017; 2(1): 1-4.
Keppel Hesselink JM. Moving targets in sodium channel blocker development: the case of raxatrigine: from a central NaV1.3 blocker via a peripheral NaV1.7 blocker to a less selective sodium channel blocker. J Med Therap 2017; 1(1):1-3. doi: 10.15761/JMT.1000104
Keppel Hesselink JM, Chiosi F, Costagliola C. Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold? Drug Des Devel Ther. 2016 Sep 27;10:3133-3141.
Keppel Hesselink JM. The terms ‘autacoid’, ‘hormone’ and ‘chalone’ and how they have shifted with time. Auton Autacoid Pharmacol. 2015 Dec;35(4):51-8. doi: 10.1111/aap.12037.
Keppel Hesselink JM, Costagliola C, Fakhry J, Kopsky DJ. Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy. J Ophthalmol. 2015;2015:430596.
Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34.
Keppel Hesselink JM. Iloperidone (Hoechst Marion Roussel Inc). IDrugs. 1999 Jun;2(6):584-90.
Langelaar G, Leeuwenkamp OR, Sterkman LG, Torreman M, Keppel Hesselink JM. The effect of nimodipine monotherapy and combined treatment with ketamine and lignocaine in aneurysmal subarachnoid haemorrhage. J Int Med Res. 1996 Sep-Oct;24(5):425-32.
Keppel Hesselink JM. The role of tumour necrosis factor α in the pathogenesis of multiple sclerosis, and pentoxifylline as a possible pharmacotherapeutic intervention. Eur J Neurol. 1995 Jul;2(3):177-80.
Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol. 1998 Jul;1(1):11-18.
Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Int Clin Psychopharmacol. 1995 Nov;10(4):251-6.
Cutler NR, Sramek JJ, Wardle TS, Keppel Hesselink JM, Roeschen JK. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial. Psychopharmacol Bull. 1993;29(2):303-8.